thymosin and Coronary-Artery-Disease

thymosin has been researched along with Coronary-Artery-Disease* in 2 studies

Reviews

1 review(s) available for thymosin and Coronary-Artery-Disease

ArticleYear
Thymosin ß4 and MRTF-A mitigate vessel regression despite cardiovascular risk factors.
    International immunopharmacology, 2023, Volume: 117

    Since clinical revascularization techniques of coronary or peripheral artery disease (CAD/PAD) focus on macrovessels of the heart, the microcirculatory compartment largely goes unnoticed. However, cardiovascular risk factors not only drive large vessel atherosclerosis, but also microcirculatory rarefaction, an instance unmet by current therapeutic schemes. Angiogenic gene therapy has the potential to reverse capillary rarefaction, but only if the disease-causing inflammation and vessel-destabilization are addressed. This review summarizes the current knowledge with regard to capillary rarefaction due to cardiovascular risk factors. Moreover, the potential of Thymosin ß4 (Tß4) and its downstream signal, myocardin-related transcription factor-A (MRTF-A), to counteract capillary rarefaction are discussed.

    Topics: Cardiovascular Diseases; Coronary Artery Disease; Heart Disease Risk Factors; Humans; Microcirculation; Microvascular Rarefaction; Risk Factors; Thymosin

2023

Other Studies

1 other study(ies) available for thymosin and Coronary-Artery-Disease

ArticleYear
Thymosin beta 4 is associated with collateral development in coronary artery disease.
    Scandinavian journal of clinical and laboratory investigation, 2011, Volume: 71, Issue:8

    Thymosin beta 4 (Tβ4) plays an essential role in cardiac vessel development and is currently being developed as a therapeutic agent for the treatment of coronary artery disease (CAD) in some experimental studies. Thus, we aimed to investigate the association of serum Tβ4 levels and collateral formation in patients presenting with severely stenotic CAD.. Thirteen patients with poor collateral development and 16 age- and sex-matched patients with good collateral development who had ≥ 95% stenosis in at least one major coronary artery on coronary angiogram (CAG) were enrolled in the study. The Gensini score was calculated for each patient by using CAG results. Collateral development was classified according to the Cohen-Rentrop method. Serum Tβ4 levels were measured with enzyme-linked immune sorbent assay.. There were no statistically significant differences between the two groups in regard to clinical and laboratory characteristics of the patients except for Tβ4 levels. The Tβ4 levels in the well-collateralized study group were found to be significantly higher than those of the poorly collateralized study group and serum Tβ4 levels were positively correlated with the collateral development.. Our findings suggest that serum Tβ4 levels are significantly associated with the collateral development in severe CAD.

    Topics: Aged; Biomarkers; Case-Control Studies; Collateral Circulation; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Coronary Vessels; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression; Humans; Male; Microfilament Proteins; Middle Aged; Odds Ratio; Research Design; Thymosin; Turkey

2011